Guardant Health Inc (GH)
17.59
+1.52
(+9.46%)
USD |
NASDAQ |
Apr 22, 16:00
17.68
+0.09
(+0.51%)
Pre-Market: 09:15
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.141B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -28.23% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.492 |
| Price to Book Value | 13.49 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 7.184 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 90.44% |
Profile
| Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
| URL | https://www.guardanthealth.com |
| Investor Relations URL | https://investors.guardanthealth.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 09, 2024 |
| Last Earnings Release | Feb. 22, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
| URL | https://www.guardanthealth.com |
| Investor Relations URL | https://investors.guardanthealth.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 09, 2024 |
| Last Earnings Release | Feb. 22, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |